Oric Pharmaceuticals, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
ORIC$9.23+4.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(98,963) | $(91,540) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 900 | 803 |
| Stock-based compensation expense | 18,759 | 15,010 |
| Accretion of discount on investments, net | (2,060) | (6,469) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | (325) | (1,211) |
| Accounts payable and accrued other liabilities | (6,798) | (1,201) |
| Net cash used in operating activities | (88,487) | (84,608) |
| Cash flows from investing activities: | ||
| Acquisitions of property and equipment | (485) | (969) |
| Purchases of investments | (354,530) | (217,294) |
| Maturities of investments | 190,000 | 197,745 |
| Net cash used in investing activities | (165,015) | (20,518) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock and pre-funded warrants | 244,369 | 125,000 |
| Issuance costs associated with financings | (2,397) | (168) |
| Proceeds from issuance of common stock under ESPP | 757 | 523 |
| Proceeds from stock option exercises | 1,035 | 617 |
| Net cash provided by financing activities | 243,764 | 125,972 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (9,738) | 20,846 |
| Cash, cash equivalents and restricted cash at beginning of period | 59,897 | 23,875 |
| Cash, cash equivalents and restricted cash at end of period | $50,159 | $44,721 |
The following table provides a reconciliation of cash, cash equivalents and restricted cash within the balance sheets to the amounts shown in the statements of cash flows above, in thousands:
| September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash and cash equivalents | $49,668 | $44,230 |
| Restricted cash included in other assets | 491 | 491 |
| Total cash, cash equivalents and restricted cash | $50,159 | $44,721 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.